1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Summary

The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

Highlights

Key Questions Answered

- Although the T2D market has numerous well-established therapies, it is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the T2D market?
- The late-stage T2D pipeline is heavily populated with me-too drugs from the classes of GLP-1 receptor agonists, DPP-4 inhibitors and SGLT-2 inhibitors. Only one drug in Phase III development is first-inclass but resembles the me-too drugs in many aspects. Will the latestage drugs make a significant impact on the T2D market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- The diagnosed prevalence of T2D in the world skyrocketed in the past 10 years and will continue increasing at the fast pace. How will epidemiological changes impact the growth of the future market?

Key Findings

- The main driver of the enormous expansion of the T2D market will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle.
- The second largest driver will be the physicians’ efforts to delay disease progression through the use of combination therapies and novel branded drugs.
- With the recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too drugs.
- In the future, companies will have to shift their focus towards competitive pricing and towards “niche” drugs aimed at smaller patient groups.
- To date, no drug has demonstrated sustainable efficacy in the treatment of T2D. This unmet need presents a large opportunity for investment by drug developers.

Scope

- Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global T2D therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
1 Table of Contents

2 Introduction 29
2.1 Catalyst 29
2.2 Related Reports 30
3 Disease Overview 31
3.1 Etiology and Pathophysiology 31
3.1.1 Etiology 31
3.1.2 Pathophysiology 32
3.1.3 Prognosis 33
3.1.4 Quality of Life 34
3.2 Symptoms 34
4 Epidemiology 36
4.1 Risk Factors and Comorbidities 36
4.1.1 Family history of diabetes is a strong predictor of type 2 diabetes 37
4.1.2 The risk of type 2 diabetes increases dramatically around age 50 38
4.1.3 The risk of developing type 2 diabetes increases as BMI increases 39
4.1.4 Gestational diabetes increases the risk of developing type 2 diabetes later in life up to 10 times 40
4.1.5 Up to 75% of adults with type 2 diabetes have hypertension 41
4.1.6 Nearly all type 2 diabetics also have dyslipidemia 42
4.2 Global Trends 43
4.2.1 US 43
4.2.2 5EU 47
4.2.3 Japan 50
4.2.4 Brazil 52
4.2.5 China and India 52
4.3 Forecast Methodology 54
4.3.1 Sources Used 57
4.3.2 Forecast Assumptions and Methods 67
4.3.3 Sources Not Used 76
4.4 Epidemiology Forecast of Type 2 Diabetes (2012-2022) 77
4.4.1 Prevalent Cases of Diagnosed Type 2 Diabetes 77
4.4.2 Age-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 79
4.4.3 Sex-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 81
4.4.4 Age-Standardized Prevalence of Diagnosed Type 2 Diabetes 83
4.4.5 Overweight/Obesity among Diagnosed Prevalent Cases of Type 2 Diabetes 84
4.4.6 Hypertension among Diagnosed Prevalent Cases of Type 2 Diabetes 86
4.4.7 Dyslipidemia among Diagnosed Prevalent Cases of Type 2 Diabetes 88
4.5 Discussion 89
4.5.1 Limitations of the Analysis 92
4.5.2 Strengths of the Analysis 93
5 Disease Management 95
5.1 Treatment Overview 95
5.1.1 Diagnosis and Referrals 95
5.1.2 Treatment Guidelines 96
5.2 US 102
5.2.1 Diagnosis 102
5.2.2 Clinical Practice 102
5.3 France 103
5.3.1 Diagnosis 103
5.3.2 Clinical Practice 103
5.4 Germany 104
5.4.1 Diagnosis 104
5.4.2 Clinical Practice 104
5.5 Italy 106
5.5.1 Diagnosis 106
5.5.2 Clinical Practice 107
5.6 Spain 109
5.6.1 Diagnosis 109
5.6.2 Clinical Practice 109
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 112
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 114
5.9 China 115
5.9.1 Diagnosis 115
5.9.2 Clinical Practice 116
5.10 India 117
5.10.1 Diagnosis 117
5.10.2 Clinical Practice 117
5.11 Brazil 118
5.11.1 Diagnosis 118
5.11.2 Clinical Practice 118
6 Competitive Assessment 119
6.1 Overview 119
6.2 Strategic Competitor Assessment 120
6.3 Product Profiles - Major Brands 122
6.3.1 Metformin 122
6.3.2 Sulfonylureas (SUs) and Other Insulin Secretagogues 127
6.3.3 ?-glucosidase Inhibitors (AGIs) 133
6.3.4 Thiazolidinediones (TZDs) 137
6.3.5 GLP-1 Receptor Agonists 142
6.3.6 DPP-4 Inhibitors 165
6.3.7 SGLT-2 Inhibitors 194
6.3.8 Insulin Formulations 204
7 Opportunity and Unmet Need 231
7.1 Overview 231
7.2 Unmet Needs 232
7.2.1 Drugs Providing Sustained Glycemic Control 232
7.2.2 Drugs with Non-Glycemic Benefits 233
7.2.3 Increased Patient Compliance 234
7.2.4 Drugs with Improved Side-Effect Profiles 235
7.2.5 Earlier Diagnosis 236
7.3 Unmet Needs Gap Analysis 237
7.4 Oral Therapy with Sustainable Efficacy 238
7.5 Oral Therapy Offering Weight Loss 238
7.6 Cardio-metabolic Therapy 239
7.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 239
8 Pipeline Assessment 240
8.1 Overview 240
8.2 Clinical Trial Mapping 241
8.2.1 Clinical Trials by Country 241
8.3 Clinical Trials by Phase and Trial Status 242
8.4 Promising Drugs in Clinical Development 244
8.4.1 Albiglutide 248
8.4.2 Dulaglutide (LY2189265) 254
8.4.3 Semaglutide 261
8.4.4 Trelagliptin (SYR-472) 266
8.4.5 MK-3102 270
8.4.6 Empagliflozin 275
8.4.7 Tofogliflozin 281
8.4.8 Ipragliflozin 286
8.4.9 LY2409021 291
8.4.10 LY2605541 (insulin peglispro) 296
9 Current and Future Players 302
9.1 Overview 302
9.2 Trends in Corporate Strategy 305
9.3 Company Profiles 306
9.3.1 Eli Lilly 306
9.3.2 Bristol-Myers Squibb 309
9.3.3 Novo Nordisk 313
9.3.4 Sanofi 316
9.3.5 GlaxoSmithKline 318
9.3.6 AstraZeneca 320
9.3.7 Merck and Co 322
9.3.8 Boehringer Ingelheim 324
9.3.9 Takeda 326
9.3.10 Roche 329
9.3.11 Pfizer 330
9.3.12 Johnson and Johnson 332
10 Market Outlook 334
10.1 Global Markets 334
10.1.1 Forecast 334
10.1.2 Drivers and Barriers - Global Issues 339
10.2 US 340
10.2.1 Forecast 340
10.2.2 Key Events 345
10.2.3 Drivers and Barriers 346
10.3 France 348
10.3.1 Forecast 348
10.3.2 Key Events 352
10.3.3 Drivers and Barriers 353
10.4 Germany 355
10.4.1 Forecast 355
10.4.2 Key Events 359
10.4.3 Drivers and Barriers 360
10.5 Italy 361
10.5.1 Forecast 361
10.5.2 Key Events 365
10.5.3 Drivers and Barriers 366
10.6 Spain 367
10.6.1 Forecast 367
10.6.2 Key Events 371
10.6.3 Drivers and Barriers 372
10.7 UK 374
10.7.1 Forecast 374
10.7.2 Key Events 378
10.7.3 Drivers and Barriers 379
10.8 Japan 381
10.8.1 Forecast 381
10.8.2 Key Events 385
10.8.3 Drivers and Barriers 386
10.9 China 388
10.9.1 Forecast 388
10.9.2 Key Events 392
10.9.3 Drivers and Barriers 393
10.10 India 395
10.10.1 Forecast 395
10.10.2 Key Events 399
10.10.3 Drivers and Barriers 399
10.11 Brazil 402
10.11.1 Forecast 402
10.11.2 Key Events 406
10.11.3 Drivers and Barriers 406
11 Appendix 410
11.1 Bibliography 410
11.2 Abbreviations 442
11.3 Methodology 445
11.4 Forecasting Methodology 445
11.4.1 Diagnosed Type 2 Patients 446
11.4.2 Percent Drug-Treated Patients 446
11.4.3 Drugs Included in Each Therapeutic Class 446
11.4.4 Launch and Patent Expiry Dates 447
11.4.5 General Pricing Assumptions 448
11.4.6 Individual Drug Assumptions 449
11.4.7 Generic Erosion 458
11.4.8 Pricing of Pipeline Agents 458
11.5 Physicians and Specialists Included in this Study 460
11.6 About the Authors 462
11.6.1 Analyst II - CVMD 462
11.6.2 Therapy Director - CVMD and Infectious Disease 462
11.6.3 Senior Epidemiologist 463
11.6.4 Global Head of Healthcare 463
11.7 About GlobalData 464
11.8 Disclaimer 464

1.1 List of Tables

Table 1: Symptoms of Type 2 Diabetes 35
Table 2: Risk Factors and Comorbidities of Type 2 Diabetes 37
Table 3: Prevalence (%) of Diabetes in Japan, 1964-1992 51
Table 4: Prevalence (%) of Diabetes in Japan, by Sex, 1997-2007 51
Table 5: Prevalence (%) of Diabetes in Japan, by Age, 2007 51
Table 6: Epidemiological Sources for Type 2 Diabetes Prevalence in the 10 Major Markets 55
Table 7: 10 Major Markets, Epidemiological Sources of Comorbidities: Overweight and Obesity 56
Table 8: Select Major Markets, Epidemiological Sources of Comorbidities: Hypertension 56
Table 9: Select Major Markets, Epidemiological Sources of Comorbidities: Dyslipidemia 57
Table 10: All Markets, Prevalent Cases of Type 2 Diabetes, Ages ?20 Years, Both Sexes, N (Millions), 2012-2022 78
Table 11: All Markets, Prevalent Cases of Type 2 Diabetes by Age, N (Millions), (Row %), 2012 80
Table 12: All Markets, Prevalent Cases of Diagnosed Type 2 Diabetes by Sex, Ages ?20 Years, N (Millions) (Row %), 2012 82
Table 13: All Markets, Prevalent Cases of Overweight/Obesity among Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 85
Table 14: All Markets, Prevalent Cases of Hypertension among Diagnosed Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 86
Table 15: All Markets, Prevalent Cases of Dyslipidemia among Diagnosed Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 88
Table 16: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 95
Table 17: Treatment Guidelines for Type 2 Diabetes 97
Table 18: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 100
Table 19: Leading Branded Treatments for Type 2 Diabetes, 2012 121
Table 20: Product Profile - Metformin 124
Table 21: Metformin SWOT Analysis, 2012 126
Table 22: Global Sales Forecasts ($m) for Metformin, 2012-2022 127
Table 23: First-Generation Sulfonylureas 129
Table 24: Second-Generation Sulfonylureas 129
Table 25: Product Profile - Sulfonylureas 130
Table 26: Sulfonylureas SWOT Analysis, 2012 131
Table 27: Global Sales Forecasts ($m) for SUs, 2012-2022 132
Table 28: Product Profile - Acarbose 134
Table 29: AGIs SWOT Analysis, 2012 136
Table 30: Global Sales Forecasts ($m) for AGIs, 2012-2022 137
Table 31: Product Profile - Actos 139
Table 32: Actos SWOT Analysis, 2012 141
Table 33: Global Sales Forecasts ($m) for Actos, 2012-2022 142
Table 34: GLP-1 Receptor Agonists 144
Table 35: Product Profile - Byetta 146
Table 36: Byetta SWOT Analysis, 2012 148
Table 37: Global Sales Forecasts ($m) for Byetta, 2012-2022 149
Table 38: Product Profile - Victoza 151
Table 39: Victoza SWOT Analysis, 2012 153
Table 40: Global Sales Forecasts ($m) for Victoza, 2012-2022 154
Table 41: Product Profile - Bydureon 156
Table 42: Bydureon SWOT Analysis, 2012 158
Table 43: Global Sales Forecasts ($m) for Bydureon, 2012-2022 159
Table 44: Product Profile - Lyxumia 161
Table 45: Lyxumia SWOT Analysis, 2012 164
Table 46: Global Sales Forecasts ($m) for Lyxumia, 2012-2022 165
Table 47: Marketed DPP-4 Inhibitors 167
Table 48: Marketed DPP-4 Inhibitors in Combination with Other OADs 167
Table 49: Product Profile - Januvia 169
Table 50: Januvia SWOT Analysis, 2012 171
Table 51: Global Sales Forecasts ($m) for Januvia and Janumet, 2012-2022 172
Table 52: Product Profile - Onglyza 174
Table 53: Onglyza SWOT Analysis, 2012 176
Table 54: Global Sales Forecasts ($m) for Onglyza and Kombiglyze, 2012-2022 178
Table 55: Product Profile - Tradjenta 179
Table 56: Tradjenta SWOT Analysis, 2012 182
Table 57: Product Profile - Galvus 185
Table 58: Galvus SWOT Analysis, 2012 188
Table 59: Global Sales Forecasts ($m) for Galvus and Eucreas, 2012-2022 189
Table 60: Product Profile - Nesina 191
Table 61: Nesina SWOT Analysis, 2012 193
Table 62: Global Sales Forecasts ($m) for Nesina and Oseni and Kazano, 2012-2022 194
Table 63: Product Profile - Forxiga 196
Table 64: Forxiga SWOT Analysis, 2012 198
Table 65: Global Sales Forecasts ($m) for Forxiga, 2012-2022 199
Table 66: Product Profile - Invokana 201
Table 67: Invokana SWOT Analysis, 2012 203
Table 68: Global Sales Forecasts ($) for Invokana, 2012-2022 204
Table 69: Insulins - Overview and Comparison 205
Table 70: Insulin Formulations 206
Table 71: Product Profile - Humalog 207
Table 72: Humalog SWOT Analysis, 2012 209
Table 73: Global Sales Forecasts ($m) for Humalog, 2012-2022 210
Table 74: Product Profile - Lantus 211
Table 75: Lantus SWOT Analysis, 2012 214
Table 76: Global Sales Forecasts ($m) for Lantus Franchise, 2012-2022 215
Table 77: Product Profile - Levemir 216
Table 78: Levemir SWOT Analysis, 2012 218
Table 79: Global Sales Forecasts ($m) for Levemir, 2012-2022 219
Table 80: Product Profile - Novolog 220
Table 81: Novolog SWOT Analysis, 2012 221
Table 82: Global Sales Forecasts ($m) for Novolog, 2012-2022 222
Table 83: Product Profile - Apidra 223
Table 84: Apidra SWOT Analysis, 2012 225
Table 85: Global Sales Forecasts ($m) for Apidra, 2012-2022 226
Table 86: Product Profile - Tresiba 227
Table 87: Tresiba SWOT Analysis, 2012 229
Table 88: Global Sales Forecasts ($) for Tresiba, 2012-2022 230
Table 89: Overall Unmet Needs - Current Level of Attainment 231
Table 90: Clinical Unmet Needs - Gap Analysis, 2013 237
Table 91: Type 2 Diabetes - Clinical Trials by Phase and Status, 2012 243
Table 92: Type 2 Diabetes - Phase Pipeline, 2012 246
Table 93: Comparison of Therapeutic Classes in Development for Type 2 Diabetes, 2012 247
Table 94: Product Profile - Albiglutide 249
Table 95: Albiglutide SWOT Analysis, 2013 253
Table 96: Global Sales Forecasts ($m) for Albiglutide, 2012-2022 254
Table 97: Product Profile - Dulaglutide 255
Table 98: Dulaglutide SWOT Analysis, 2012 259
Table 99: Global Sales Forecasts ($m) for Dulaglutide, 2012-2022 260
Table 100: Product Profile - Semaglutide 262
Table 101: Semaglutide SWOT Analysis, 2012 264
Table 102: Global Sales Forecasts ($m) for Semaglutide, 2012-2022 265
Table 103: Product Profile - Trelagliptin 267
Table 104: Trelagliptin SWOT Analysis, 2013 269
Table 105: Global Sales Forecasts ($m) for Trelagliptin, 2012-2022 270
Table 106: Product Profile - MK-3102 271
Table 107: MK-3102 SWOT Analysis, 2013 273
Table 108: Global Sales Forecasts ($m) for MK-3102, 2012-2022 274
Table 109: Product Profile - Empagliflozin 276
Table 110: Empagliflozin SWOT Analysis, 2013 279
Table 111: Global Sales Forecasts ($m) for Empagliflozin, 2012-2022 280
Table 112: Product Profile - Tofogliflozin 282
Table 113: Tofogliflozin SWOT Analysis, 2013 284
Table 114: Global Sales Forecasts ($m) for tofogliflozin, 2012-2022 285
Table 115: Product Profile - Ipragliflozin 287
Table 116: Ipragliflozin SWOT Analysis, 2013 289
Table 117: Global Sales Forecasts ($m) for Ipragliflozin, 2012-2022 290
Table 118: Product Profile - LY2409021 292
Table 119: LY2409021 SWOT Analysis, 2013 294
Table 120: Global Sales Forecasts ($m) for LY2409021, 2012-2022 295
Table 121: Product Profile - LY2605541 297
Table 122: LY2605541 SWOT Analysis, 2013 300
Table 123: Global Sales Forecasts ($) for LY2605541, 2012-2022 301
Table 124: Key Companies in the Type 2 Diabetes Market, 2012 303
Table 125: Other Companies in the Type 2 Diabetes Market, 2012 304
Table 126: Eli Lilly's Type 2 Diabetes Portfolio Assessment, 2013 308
Table 127: Eli Lilly SWOT Analysis, 2012 309
Table 128: Bristol-Myers Squibb's Type 2 Diabetes Portfolio Assessment, 2013 311
Table 129: Bristol-Myers Squibb SWOT Analysis, 2012 312
Table 130: Novo Nordisk's Type 2 Diabetes Portfolio Assessment, 2013 314
Table 131: Novo Nordisk SWOT Analysis, 2012 315
Table 132: Sanofi's Type 2 Diabetes Portfolio Assessment, 2013 317
Table 133: Sanofi SWOT Analysis, 2012 318
Table 134: GSK's Type 2 Diabetes Portfolio Assessment, 2013 319
Table 135: GSK SWOT Analysis, 2012 320
Table 136: AstraZeneca's Type 2 Diabetes Portfolio Assessment, 2013 321
Table 137: AstraZeneca SWOT Analysis, 2012 322
Table 138: Merck's Type 2 Diabetes Portfolio Assessment, 2013 323
Table 139: Merck SWOT Analysis, 2012 324
Table 140: Boehringer Ingelheim's Type 2 Diabetes Portfolio Assessment, 2013 325
Table 141: Boehringer Ingelheim SWOT Analysis, 2012 326
Table 142: Takeda's Type 2 Diabetes Portfolio Assessment, 2013 328
Table 143: Takeda SWOT Analysis, 2012 328
Table 144: Roche's Type 2 Diabetes Portfolio Assessment, 2013 329
Table 145: Roche SWOT Analysis, 2012 330
Table 146: Pfizer's Type 2 Diabetes Portfolio Assessment, 2013 331
Table 147: Pfizer SWOT Analysis, 2012 331
Table 148: JandJ's Type 2 Diabetes Portfolio Assessment, 2013 332
Table 149: JandJ SWOT Analysis, 2012 333
Table 150: Global Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 336
Table 151: Type 2 Diabetes Market - Drivers and Barriers, 2012 339
Table 152: US Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 342
Table 153: Key Events Impacting Sales for Type 2 Diabetes in the US, 2012-2022 345
Table 154: Type 2 Diabetes Market - Drivers and Barriers in the US, 2012 346
Table 155: France Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 349
Table 156: Key Events Impacting Sales for Type 2 Diabetes in France, 2012-2022 352
Table 157: Type 2 Diabetes Market - Drivers and Barriers in France, 2012 353
Table 158: Germany Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 356
Table 159: Key Events Impacting Sales for Type 2 Diabetes in Germany, 2012-2022 359
Table 160: Type 2 Diabetes Market - Drivers and Barriers in Germany, 2012 360
Table 161: Italy Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 362
Table 162: Key Events Impacting Sales for Type 2 Diabetes in Italy, 2012-2022 365
Table 163: Type 2 Diabetes Market - Drivers and Barriers in Italy, 2012 366
Table 164: Spain Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 368
Table 165: Key Events Impacting Sales for Type 2 Diabetes in Spain, 2012-2022 371
Table 166: Type 2 Diabetes Market - Drivers and Barriers in Spain, 2012 372
Table 167: UK Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 375
Table 168: Key Events Impacting Sales for Type 2 Diabetes in the UK, 2012-2022 378
Table 169: Type 2 Diabetes Market - Drivers and Barriers in the UK, 2012 379
Table 170: Japan Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 382
Table 171: Key Events Impacting Sales for Type 2 Diabetes in Japan, 2012-2022 385
Table 172: Type 2 Diabetes Market - Drivers and Barriers in Japan, 2012 386
Table 173: China Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 389
Table 174: Key Events Impacting Sales for Type 2 Diabetes in China, 2012-2022 392
Table 175: Type 2 Diabetes Market - Drivers and Barriers in China, 2012 393
Table 176: India Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 396
Table 177: Key Events Impacting Sales for Type 2 Diabetes in India, 2012-2022 399
Table 178: Type 2 Diabetes Market - Drivers and Barriers in India, 2012 399
Table 179: Brazil Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 403
Table 180: Key Events Impacting Sales for Type 2 Diabetes in Brazil, 2012-2022 406
Table 181: Type 2 Diabetes Market - Drivers and Barriers in Brazil, 2012 406
Table 182: Key Launch Dates 447
Table 183: Key Patent Expiries 447
Table 184: Number of High-Prescribing Physicians Surveyed 461

1.2 List of Figures
Figure 1: Crude and Age-Adjusted Incidence (per 1,000 population) of Diagnosed Diabetes in the US, Ages 18-79 Years, 1980-2011 44
Figure 2: Crude and Age-Adjusted Prevalence (%) of Diagnosed Diabetes in the US, Ages ?18 Years, 1980-2010 45
Figure 3: Age-Specific Prevalence of Diagnosed Diabetes in the US, 1980-2011 46
Figure 4: Age-Adjusted Prevalence of Diagnosed Diabetes in the US, by Sex, Ages ?18 Years, 1980-2011 46
Figure 5: Age-Adjusted Prevalence (%) of Diagnosed Diabetes, France, Germany and Italy, 1999-2007 48
Figure 6: Age-Adjusted Prevalence (%) of Diagnosed Type 2 Diabetes in Spain, 1987-2006, by Sex, 1987-2006 49
Figure 7: Age-Adjusted Prevalence (%) of Diagnosed Diabetes in the UK, 1996-2011 49
Figure 8: Age-Adjusted Prevalence (%) of Diagnosed Diabetes, UK, 1994-1998, by Sex 50
Figure 9: Urban-Rural Differences in the Age-Adjusted Prevalence (%) of Diabetes in China and India, 1992-2008 53
Figure 10: All Markets, Prevalent Cases of Type 2 Diabetes, Ages ?20 Years, N (Millions), 2012-2022 78
Figure 11: All Markets, Prevalent Cases of Diagnosed Type 2 Diabetes, by Age, N (Millions), 2012 81
Figure 12: All Markets, Prevalent Cases of Diagnosed Type 2 Diabetes by Sex, Ages ?20 Years, N (Millions), 2012 82
Figure 13: All Markets, Age-Standardized Prevalence of Diagnosed Type 2 Diabetes, Ages ?20 Years, Men and Women, %, 2012 84
Figure 14: All Markets, Prevalent Cases of Overweight/Obesity among Diagnosed Type 2 Diabetes, Both Sexes, Ages ?20 Years, N (Millions), 2012 85
Figure 15: All Markets, Prevalent Cases of Hypertension among Diagnosed Type 2 Diabetes, Both Sexes, Ages ?20 Years, N (Millions), 2012 87
Figure 16: All Markets, Prevalent Cases of Dyslipidemia among Diagnosed Type 2 Diabetics, Both Sexes, Ages ?20 Years, N (Millions), 2012 89
Figure 17: ADA/EASD General Recommendations for Antihyperglycemic Therapy 99
Figure 18: Type 2 Diabetes Therapeutics - Clinical Trials by Country, 2012 242
Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Type 2 Diabetes, 2012-2022 247
Figure 20: Company Portfolio Gap Analysis in Type 2 Diabetes, 2012-2022 304
Figure 21: Global Sales for Type 2 Diabetes by Region, 2011-2022 338
Figure 22: Sales for Type 2 Diabetes in the US by Drug Class, 2012-2022 344
Figure 23: Sales for Type 2 Diabetes in France by Drug Class, 2012-2022 351
Figure 24: Sales for Type 2 Diabetes in Germany by Drug Class, 2012-2022 358
Figure 25: Sales for Type 2 Diabetes in Italy by Drug Class, 2012-2022 364
Figure 26: Sales for Type 2 Diabetes in Spain by Drug Class, 2012-2022 370
Figure 27: Sales for Type 2 Diabetes in the UK by Drug Class, 2012-2022 377
Figure 28: Sales for Type 2 Diabetes in Japan by Drug Class, 2012-2022 384
Figure 29: Sales for Type 2 Diabetes in China by Drug Class, 2012-2022 391
Figure 30: Sales for Type 2 Diabetes in India by Drug Class, 2012-2022 398
Figure 31: Sales for Type 2 Diabetes in Brazil by Drug Class, 2012-2022 405

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Diabetic foot ulcers (DFUs)- Market Insights, Epidemiology and Market Forecast-2023

Diabetic foot ulcers (DFUs)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Diabetic foot ulcers (DFUs) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Diabetic foot ulcers (DFUs) - Epidemiology Forecast To 2023

Diabetic foot ulcers (DFUs) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Diabetic foot ulcers (DFUs) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Diabetic foot ulcers (DFUs) in seven major markets (US, France, Germany, ...

Type 2 Diabetes Disease : Patent Overview (Last 5 years)

Type 2 Diabetes Disease : Patent Overview (Last 5 years)

  • $ 2000
  • Industry report
  • November 2016
  • by Mordor Intelligence LLP

The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.this is claimed in ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.